Reference | Cohort | Group | N | Gender (M/F) | Mean age (years) | Mean MMSE | Neuropsychological criteria | Biomarkers |
---|---|---|---|---|---|---|---|---|
Arenaza-Urquijo et al., 2017 [69] | IMAP+ | CN | 73 | 39/34 | 66.9 | 29.0 | MMSE score ≥ 28 | AV45-PET |
Barthel et al., 2011 [77] | FBB phase 2 study | CN | 68 | 30/38 | 68.2 | NA | CDR = 0; MMSE score ≥ 28 | FBB-PET |
Besson et al., 2015 [78] | IMAP | CN | 54 | 27/27 | 65.8 | 29.0 | Cognitive performance > 5th percentile | AV45-PET |
Brier et al., 2016 [79] | Washington University ACS-KADRC | CN | 157 | 50/107 | 53.1 | 29.2 | CDR = 0 | PiB-PET |
Byun et al., 2017 [80] | KBASE | CN | 205 | 98/107 | 68.5 | NA | CDR = 0 | PiB-PET |
Cho et al., 2016 [81] | Memory Clinic Gangnam Hospital | CN | 67 | 25/42 | 66.1 | 28.1 | No neuropsychological deficits | FBB-PET |
Clark et al., 2018 [82] | WRAP | CN | 314 | 96/218 | 61.5 | NA | No neuropsychological deficits | CSF—NIA-AA criteria |
Dubois et al., 2018 [56] | INSIGHT_preAD | CN | 318 | 117/201 | 76.0 | 28.7 | Cognitive complaints; MMSE score ≥ 27, CDR = 0, FCSRT total recall score ≥ 41 | AV45-PET |
Eckerström et al., 2017 [72] | Gothenburg MCI Study | SCD | 113 | 37/76 | 62.0 | 28.0 | Cognitive complaints (> 6 months) | CSF—NIA-AA criteria |
Edmonds et al., 2015 [11] | ADNI | CN | 570 | 308/262 | 73.0 | NA | No neuropsychological deficits | CSF—NIA-AA criteria |
Gordon et al., 2015 [68] | WU-KADRC | CN | 397 | 141/257 | 67.1 | 29.2 | CDR = 0 | PiB-PET |
Harrington et al., 2013 [83] | Huntington Hospital—Pasadena | CN | 70 | 27/43 | 77.2 | NA | CDR = 0; FAQ = 0; no neuropsychological deficits | CSF Aβ42/t-tau ratio |
Hatashita and Yamasaki, 2010 [84] | Shonan Atsugi Hospital—Japan | CN | 91 | 45/46 | 65.1 | 29.3 | CDR = 0; MMSE score ≥ 28 | PiB-PET |
Johnson et al., 2013 [85] | AV45-A11 study | CN | 78 | 34/44 | 69.4 | 29.6 | MMSE score ≥ 29; no neuropsychological deficits | PiB-PET |
Kern et al., 2018 [15] | H70 Gothenburg Birth Cohort Studies | CN | 259 | 130/129 | 70.6 | 29.3 | CDR = 0 | CSF—NIA-AA criteria |
Knopman et al., 2012 [73] | MCSA | CN | 529 | 289/240 | 78.3 | 28 | No neuropsychological deficits | PiB-PET |
Lilamand et al., 2016 [86] | MAPT | CN | 271 | 108/163 | 76.0 | 28.2 | CDR = 0 | PiB-PET |
Lim et al., 2014 [87] | University of Pittsburgh ADRC and Pepper Registry | CN | 56 | 19/37 | 75.8 | 28.5 | CDR = 0; MMSE score > 27 | PiB-PET |
Lim et al., 2016 [31] | AIBL | CN | 423 | 192/231 | 69.4 | 28.8 | No neuropsychological deficits | PiB-PET |
Mandecka et al., 2016 [58] | Cracow Hospital—Memory Clinic | SCD | 85 | 28/57 | 61.3 | NA | Cognitive complaints | CSF Aβ42 and t-tau |
Meyer et al., 2018 [88] | PreventAD | CN | 101 | 31/70 | 62.9 | NA | MoCA ≥ 23 | CSF—NIA-AA criteria |
Montal et al., 2018 [89] | Spain cohorts | CN | 254 | 141/113 | 58.6 | 28.9 | No cognitive complaints; CDR = 0; no neuropsychological deficits | CSF—NIA-AA criteria |
Ossenkoppele et al., 2014 [90] | BACS | CN | 81 | 29/52 | 75.0 | 29.0 | No cognitive complaints; no neuropsychological deficits | PiB-PET |
Papp et al., 2017 [28] | HABS | CN | 279 | 114/165 | 73.4 | 29.0 | CDR = 0; no deficits on Logical Memory Story A, Delayed Recall, and MMSE | PiB-PET |
Rodrigue et al., 2012 [91] | DLBS | CN | 137 | NA/NA | 64.0 | 29.3 | No neuropsychological deficits | AV45-PET |
Schoonenboom et al., 2012 [92] | VU Medical Center, Alzheimer Center, Amsterdam | SMC | 275 | 151/124 | 59.0 | 29.0 | No neuropsychological deficits | CSF Aβ42,t-tau, p-tau |
Snyder et al., 2016 [70] | Rhode Island and Alzheimer Assessment Trial Match | CN | 63 | 24/39 | 62.8 | 29.1 | MMSE score ≥ 27; no neuropsychological deficits | AV45-PET |
Soldan et al., 2016 [26] | BIOCARD | CN | 222 | 89/133 | 56.9 | 29.5 | No neuropsychological deficits | CSF Aβ42, t-tau, p-tau |
Taylor et al., 2017 [93] | APEX | CN | 128 | 34/94 | 71.3 | 29.0 | CDR = 0; no neuropsychological deficits | PiB-PET |
Um et al., 2017 [94] | Catholic Geriatric Neuroimaging Database | CN | 50 | 18/32 | 68.0 | 28.5 | CDR = 0; MMSE score > 27 | FBB-PET |
Van Harten et al., 2013 [95] | Amsterdam Dementia Cohort | SMC | 132 | 76/56 | 61.4 | 28.3 | Cognitive complaints; no neuropsychological deficits | CSF—NIA-AA criteria |
Visser et al., 2009 [59] | DESCRIPA | CN | 89 | 41/48 | 67.1 | 29.3 | No neuropsychological deficits | CSF Aβ42/tau |
SCI | 60 | 31/29 | 66.0 | 28.8 | Cognitive complaints; no neuropsychological deficits | CSF Aβ42/tau | ||
Wolfsgruber et al., 2015 [96] | DCN | SCD | 82 | 58/24 | 66.7 | 27.7 | No neuropsychological deficits | CSF Aβ42/t-tau |
Zhao et al., 2018 [57] | GEM | CN | 175 | 104/71 | 86.0 | NA | No neuropsychological deficits | PiB-PET |